<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580992</url>
  </required_header>
  <id_info>
    <org_study_id>APA Brugada study</org_study_id>
    <nct_id>NCT04580992</nct_id>
  </id_info>
  <brief_title>Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial</brief_title>
  <official_title>Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Brugada Syndrome is an inherited channelopathy associated with risk of&#xD;
      ventricular fibrillation and sudden cardiac death in a structurally normal heart. The&#xD;
      diagnosis is based on the characteristic electrocardiographic pattern (coved type STsegment&#xD;
      elevation, 2mm followed by a negative T-wave in one or more of the right precordial leads V1&#xD;
      to V2), noted spontaneously or upon administration of a sodiumchannel blocker, such as&#xD;
      Ajmaline.&#xD;
&#xD;
      The majority of adults screened for Brugada Syndrome, undergo the Ajmaline provocation-test&#xD;
      awake. Ajmaline is therefore injected continuously, with incremental steps through an&#xD;
      intravenous placed catheter, according to cardiological protocols. In a subpopulation of&#xD;
      anxious adults, or when another electrophysiological procedure is required at the same time,&#xD;
      sedation or general anaesthesia is provided. Similarly, in the paediatric population, it is&#xD;
      common practice to perform the challenge test under sedation.&#xD;
&#xD;
      Based on the sodium channel blocking properties of propofol, it is not unthinkable that&#xD;
      anaesthetic agents might interact with the pharmacodynamic or pharmacokinetic effects of&#xD;
      Ajmaline on the myocardial sodium channels. Existence of such interaction would implicate&#xD;
      altered diagnostic value of the Ajmaline-provocation-test for patients that undergo the&#xD;
      challenge under general anaesthesia.&#xD;
&#xD;
      Objective: The goal of this study is to evaluate if the Ajmaline-provocation-test results in&#xD;
      altered electrocardiographic effects when performed under general anaesthesia with propofol.&#xD;
&#xD;
      Study-design: A prospective observational study.&#xD;
&#xD;
      Study population: Patients are eligible for inclusion if they have been diagnosed with&#xD;
      Brugada Syndrome, are American Society of Anaesthesiologists (ASA) 2 - 4, older than 18 years&#xD;
      and are scheduled for epicardial ablation. Exclusion criteria are known allergy for propofol,&#xD;
      a body mass index (BMI) above 35 for female and 42 for male patients, obstetric patients,&#xD;
      critical illness, conditions that exclude continuous propofol infusion due to higher risk for&#xD;
      propofol infusion syndrome (PRIS), such as mitochondrial disease, fatty acid oxidation&#xD;
      disorder, co-enzyme Q deficiency and any other condition that renders the patient unfit for&#xD;
      elective surgery.&#xD;
&#xD;
      Intervention: This study is prospective, observational.&#xD;
&#xD;
      Main study parameters/endpoints: The primary endpoints are changes in the ST-, Jp-, QRS-,&#xD;
      T(p-e)-segments and T(p-e)/QT -ratio changes during steady-state anaesthesia. The secondary&#xD;
      endpoint is the occurrence of de novo arrhythmias.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation: This is an&#xD;
      observational study; therefore, the risks associated are no other than those associated with&#xD;
      the intervention itself. No additional blood-samples, tests or consults are necessitated&#xD;
      during participation; therefore, no extra burden is associated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 16, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ST-, QRS-, Jp-, QT-, QTcB-, QTcFr- and JT-interval</measure>
    <time_frame>during the intervention/procedure/surgery</time_frame>
    <description>Ventricular Arrhythmogenesis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malignant arrhythmias</measure>
    <time_frame>intra- or postoperatively (up to 24hours upon discharge from the post anaesthetic care unit)</time_frame>
    <description>Previously not-known or non-existing ventricular or supraventricular arrhythmias resulting in compromising hemodynamic instability detrimentally affecting cardiac output and requiring advanced cardiac life treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Brugada Syndrome</condition>
  <condition>Channelopathies</condition>
  <condition>Ventricular Fibrillation</condition>
  <condition>Cardiac Death</condition>
  <arm_group>
    <arm_group_label>Ajmaline group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ajmaline</intervention_name>
    <description>Ajmaline administration</description>
    <arm_group_label>Ajmaline group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are eligible for inclusion upon the age of 18, diagnosed with Brugada Syndrome and&#xD;
        when epicardial ablation was indicated as treatment. In this study, we would like to&#xD;
        include at least twenty-five patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 year&#xD;
&#xD;
          -  ASA 2, 3, 4&#xD;
&#xD;
          -  Epicardial ablation indicated by cardiologist&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A known allergy to propofol&#xD;
&#xD;
          -  BMI&gt;35 for female patients&#xD;
&#xD;
          -  BMI &gt; 42 for male patients&#xD;
&#xD;
          -  Obstetric anaesthesia&#xD;
&#xD;
          -  Critical Illness&#xD;
&#xD;
          -  Mitochondrial disease&#xD;
&#xD;
          -  Fatty acid oxidation disorder&#xD;
&#xD;
          -  Co-enzyme Q deficiency&#xD;
&#xD;
          -  Any condition that renders the patient unfit for elective surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evelien Vandeurzen</last_name>
    <phone>024749237</phone>
    <email>evelien.vandeurzen@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dirk De Clippeleir</last_name>
    <email>dirk.declippeleir@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelien Vandeurzen</last_name>
      <email>evelien.vandeurzen@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Panagiotis Flamee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Fibrillation</mesh_term>
    <mesh_term>Brugada Syndrome</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Channelopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ajmaline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

